TCL Archive High Response Rate of Hairy Cell Leukemia Patients to Immunotoxin Treatment In Phase I April 27, 2001
TCL Archive Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial October 26, 2012
TCL Archive NCI Committed To 50 Percent Mortality Reduction By 2000; DCPC Board Hears How That Will Be Done January 20, 1984
TCL Archive In Brief: CREG To Be Used In Viral Oncology, Nutrition, Cell Kinetics, Immunology, Rauscher Tells NCAB April 4, 1975